HK1201452A1 - 降低心血管疾病風險的方法 - Google Patents

降低心血管疾病風險的方法

Info

Publication number
HK1201452A1
HK1201452A1 HK15101958.1A HK15101958A HK1201452A1 HK 1201452 A1 HK1201452 A1 HK 1201452A1 HK 15101958 A HK15101958 A HK 15101958A HK 1201452 A1 HK1201452 A1 HK 1201452A1
Authority
HK
Hong Kong
Prior art keywords
methods
cardiovascular disease
reducing risk
risk
reducing
Prior art date
Application number
HK15101958.1A
Other languages
English (en)
Inventor
Charles L Bisgaier
Original Assignee
Gemphire Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gemphire Therapeutics Inc filed Critical Gemphire Therapeutics Inc
Publication of HK1201452A1 publication Critical patent/HK1201452A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK15101958.1A 2012-01-06 2015-02-27 降低心血管疾病風險的方法 HK1201452A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261584002P 2012-01-06 2012-01-06
PCT/US2013/020317 WO2013103842A1 (en) 2012-01-06 2013-01-04 Methods of reducing risk of cardiovascular disease

Publications (1)

Publication Number Publication Date
HK1201452A1 true HK1201452A1 (zh) 2015-09-04

Family

ID=48745439

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15101958.1A HK1201452A1 (zh) 2012-01-06 2015-02-27 降低心血管疾病風險的方法

Country Status (9)

Country Link
US (2) US10028926B2 (zh)
EP (2) EP2800564B1 (zh)
JP (2) JP6295205B2 (zh)
CN (2) CN104136023A (zh)
AU (1) AU2013207423B2 (zh)
CA (1) CA2861643C (zh)
HK (1) HK1201452A1 (zh)
MX (1) MX367352B (zh)
WO (1) WO2013103842A1 (zh)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
WO2012045082A2 (en) 2010-10-01 2012-04-05 Jason Schrum Engineered nucleic acids and methods of use thereof
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3682905B1 (en) 2011-10-03 2021-12-01 ModernaTX, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
DK2791160T3 (da) 2011-12-16 2022-05-30 Modernatx Inc Modificerede mrna-sammensætninger
US9440754B2 (en) 2012-03-29 2016-09-13 R.P. Scherer Technologies, Llc Three circuit fill system for blow fill seal containers
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
DE18200782T1 (de) 2012-04-02 2021-10-21 Modernatx, Inc. Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
HRP20220607T1 (hr) 2012-11-26 2022-06-24 Modernatx, Inc. Terminalno modificirana rna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
SG11201507496UA (en) 2013-04-17 2015-11-27 Pfizer N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
JP2017533973A (ja) 2014-11-14 2017-11-16 ジェムフィアー セラピューティクス インコーポレイテッド α，ω−ジカルボン酸末端ジアルカンエーテルを調製するためのプロセスおよび中間体
CN114099496A (zh) * 2015-03-13 2022-03-01 艾斯柏伦治疗公司 含etc1002和依泽替米贝的组合及治疗方法
MA41793A (fr) * 2015-03-16 2018-01-23 Esperion Therapeutics Inc Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
AU2016348638A1 (en) 2015-11-06 2018-06-07 Gemphire Therapeutics Inc. Gemcabene combinations for the treatment of cardiovascular disease
RU2018133690A (ru) * 2016-02-26 2020-03-26 Джемфир Терапьютикс Инк. Лечение пациентов с гомозиготной семейной гиперхолестеринемией, получающих липидоснижающую терапию
JP2020506241A (ja) * 2017-02-08 2020-02-27 エスペリオン・セラピューティクス・インコーポレイテッドＥｓｐｅｒｉｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． トリプレット組み合わせ製剤、及び心血管疾患を治療又はそのリスクを低下させる方法
EP3612171A4 (en) * 2017-04-18 2020-10-21 Gemphire Therapeutics Inc. GEMCABED, PHARMACEUTICAL SALT THEREOF, COMPOSITIONS THEREOF, AND METHOD OF USE THEREOF
US20190008779A1 (en) * 2017-05-11 2019-01-10 Gemphire Therapeutics Inc. Gemcabene compositions and methods of use thereof
CN109666727B (zh) * 2018-12-29 2020-11-06 中国药科大学 一种高活性抑制pcsk9表达的微小rna的用途
EP3986859A1 (en) 2019-06-21 2022-04-27 Esperion Therapeutics, Inc. Methods of making bempedoic acid and compositions of the same
CN113134086B (zh) * 2020-01-20 2024-05-24 深圳市长卿医学研究院 一种降血脂的药物组合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648387A (en) 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
US20020103252A1 (en) 1997-12-12 2002-08-01 Bisgaier Charles Larry Statin-carboxyalkylether combinations
NZ503982A (en) * 1997-12-12 2002-03-28 Warner Lambert Co Statin-carboxyalkylether combinations useful for treating vascular disorders and diabetes mellitus
US6861555B2 (en) 2000-01-25 2005-03-01 Warner-Lambert Company Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith
WO2000059855A1 (en) 1999-04-01 2000-10-12 Esperion Therapeutics, Inc. Ether compounds, compositions, and uses thereof
EP1351916A2 (en) 2000-10-11 2003-10-15 Esperion Therapeutics Inc. Ether compounds and compositions for cholesterol management and related uses
US6645170B2 (en) 2001-03-05 2003-11-11 Bioject Medical Technologies, Inc. Simplified disposable needle-free injection apparatus and method
US20040229954A1 (en) * 2003-05-16 2004-11-18 Macdougall Diane Elaine Selective manipulation of triglyceride, HDL and LDL parameters with 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt
US7345190B2 (en) 2003-11-12 2008-03-18 Ssv Therapeutics, Inc. Carnitine conjugates as dual prodrugs and uses thereof
WO2007067817A1 (en) 2005-12-07 2007-06-14 Cv Therapeutics, Inc. Abca1 elevating compounds
US8377971B2 (en) * 2006-08-03 2013-02-19 Trustees Of Tufts College Non-flushing niacin analogues, and methods of use thereof

Also Published As

Publication number Publication date
JP2018104452A (ja) 2018-07-05
EP3735967A1 (en) 2020-11-11
JP2015503588A (ja) 2015-02-02
US20180303779A1 (en) 2018-10-25
US20150005386A1 (en) 2015-01-01
EP2800564B1 (en) 2020-05-06
MX367352B (es) 2019-08-16
AU2013207423B2 (en) 2017-10-12
US10028926B2 (en) 2018-07-24
AU2013207423A1 (en) 2014-07-24
CA2861643C (en) 2020-10-06
EP2800564A4 (en) 2015-07-22
EP2800564A1 (en) 2014-11-12
CA2861643A1 (en) 2013-07-11
WO2013103842A1 (en) 2013-07-11
MX2014008180A (es) 2014-10-14
CN110025608A (zh) 2019-07-19
JP6295205B2 (ja) 2018-03-14
US10709678B2 (en) 2020-07-14
CN104136023A (zh) 2014-11-05

Similar Documents

Publication Publication Date Title
HK1201452A1 (zh) 降低心血管疾病風險的方法
HK1211844A1 (zh) 肺部疾病的治療
HK1208363A1 (zh) 新方法
HUE037048T2 (hu) Eljárások 4-cikloalkiloxibenzolszulfonamidok elõállítására
ZA201406082B (en) Use of ccr3-inhibitors
GB201311220D0 (en) Improved structure of shoe
PT2739750T (pt) Doença cardiovascular
EP2852403A4 (en) METHOD FOR MODIFYING TISSUE
PL2931937T3 (pl) Sposób wytwarzania układów nanocząstek metali
IL236312A0 (en) Preparation of 18f-flucyclobin
EP2881113A4 (en) NEW APPLICATION OF POGOSTONE
GB201220155D0 (en) Method of manufacture
IL237862A0 (en) Methods to reduce the formation of scale
GB201201062D0 (en) Radiofluorination method
GB201312378D0 (en) Structure of shoe
EP2892529A4 (en) USES OF (-) - PERHEXILINE
EP2887938A4 (en) PROCESS FOR PREPARING TECOVIRIMAT
GB201215942D0 (en) Method of treatent
GB201207907D0 (en) Treatment of depression
EP2823074A4 (en) NICKEL-ALUMINUM-ZIRCONIUM ALLOYS
GB201219092D0 (en) Treatment of cardiovascular disease
ZA201503833B (en) Method of hemoglobin-f determination
GB201118269D0 (en) Treatment of cardiovascular disease
GB201107988D0 (en) Treatment of cardiovascular disease
TWM433525U (en) Structure of calorifier